Crinetics Pharmaceuticals is a leading pharmaceutical company dedicated to developing innovative therapies for individuals with rare endocrine diseases. Our mission is to provide effective disease control and simplify the lives of patients facing these challenging conditions. We focus exclusively on endocrine diseases, making us a unique player in the industry.

Many patients have longed for better therapies that improve symptoms and enhance their quality of life, and we're committed to making this a reality. One of our noteworthy developments is paltusotine, an oral treatment for acromegaly. This groundbreaking therapy offers hope to patients and their families, providing a much-needed solution for this rare endocrine disease.

Our comprehensive pipeline includes studies in Phase 3 for acromegaly, as well as research into other conditions like carcinoid syndrome, Cushing's disease, and hyperparathyroidism. At Crinetics, we believe in a patient-centric approach, collaborating with healthcare practitioners to address their real-world needs. We also strive to build value for investors by meeting market demands and delivering innovative solutions.

With our focused intensity and dedication, we're committed to improving patients' lives and making a positive impact in the field of endocrinology. Welcome to Crinetics Pharmaceuticals, where better therapies lead to better lives